Lacta-Stop (Cabergoline) Oral Solution, 15 ml (Antilac analog)
Cabergoline for against the symptoms of false pregnancy
Solution for oral administration.
Composition and form of release
Cabergoline – 50 μg / ml, auxiliary components.
The drug is available in 7 and 15 ml PET dropper bottles in a cardboard box and instructions for use.
Cabergoline, which is part of the drug, is a derivative of ergot alkaloids, a prolonged-acting dopamine receptor agonist. It has high affinity for D2-dopamine receptors, low affinity for D1-dopamine, alpha1- and alpha2-adrenergic, 5-HT1- and 5-HT2-serotonin receptors.
Prevents and suppresses physiological lactation. The use of Lacto-stop prevents lactation, enlargement of the mammary glands and the development of lactational mastitis. A decrease in prolactin levels contributes to the rapid disappearance of the signs of false pregnancy, as well as changes in the behavior of the animal. When used simultaneously with dopamine receptor blockers, the effectiveness of Lacto-Stop decreases.
The equilibrium concentration of cabergoline after repeated administration within a week exceeds that after a single dose by 2-3 times. The absolute bioavailability of cabergoline is unknown; a significant portion of the dose taken undergoes a “first pass” effect through the liver. Plasma protein binding does not depend on plasma concentration and is 40–42%. Cabergoline and / or its metabolites are well distributed in tissues: in animal studies measuring total radioactivity, a more than 100-fold increase in the concentration of cabergoline and / or its metabolites in the pituitary gland was found in comparison with their content in blood plasma.
Cabergoline is excreted by the kidneys and intestines (22% and 60%, respectively) within 20 days; less than 4% was found in the urine unchanged. Renal excretion in animals with hyperprolactinemia is similar to that in healthy animals. In studies on animals with moderate to severe renal insufficiency, no changes in the pharmacokinetics of cabergoline were detected. According to the available data, there were no differences in the response to cabergoline therapy between animals of different ages. The time of the onset of the maximum effect was 48 hours, the duration of action of cabergoline reached 14 days. In studies, the selectivity of the action of cabergoline was noted: there was no effect on the secretion of other hormones produced by the anterior pituitary gland (STH, FSH, LH, ACTH, TSH), or cortisol. No carcinogenic or mutagenic properties have been identified. Found in milk
Lacto-Stop, according to the degree of impact on the body, belongs to low-hazard substances (hazard class 4 according to GOST 12.1.007-76).
Indications for use
Lacto-Stop is prescribed to dogs for the treatment of falsehood and suppression of lactation for clinical reasons (eg, early weaning of puppies), as well as for hyperprolactinemia, idiopathic or caused by a pituitary adenoma.
It is forbidden to use Lacto-stop during pregnancy due to the increased likelihood of abortion. It is not recommended to use animals with hypotension or simultaneously with antihypertensive drugs, or animals under the influence of anesthetic drugs, as well as after surgery due to the possible increase in the hypotensive effect of the drug.
Method of administration and dosage
The drug is administered orally together with food or forcibly on the root of the tongue in a dose of 0.1 ml (3 drops) per 1 kg of animal weight once a day for 4-6 days. If there is no effect or the appearance of false symptoms after stopping the administration of the drug, the course can be repeated.
*Kilograms to Pounds conversion table
|Kilograms (kg)||Pounds (lb)||Pounds+Ounces
|0.1 kg||0.220 lb||0 lb 3.527 oz|
|1 kg||2.205 lb||2 lb 3.274 oz|
|5 kg||11.023 lb||11 lb 0.370 oz|
|10 kg||22.046 lb||22 lb 0.740 oz|
When using Lacto-Stop in accordance with this instruction, side effects and complications in animals, as a rule, are not observed. Very rarely, in some animals in the first two days of treatment, a single vomiting, lack of appetite or drowsiness may be observed, which does not require discontinuation of the drug.
In case of an overdose, possible: nasal congestion, vomiting, fainting, hallucinations. In case of an overdose, supportive symptomatic therapy is performed to suppress vomiting and restore blood pressure. As an antidote, metoclopramide is used, symptomatic, maintaining blood pressure.
If one or more doses of the drug are missed, its use is resumed in the same dosage and according to the same scheme.
Interaction with other medicinal products
Should not be used concomitantly with dopamine D2 receptor antagonists (phenothiazine, butyrophenone, thioxanthene, metoclopramide derivatives). Concomitant use with drugs that have a high degree of binding to plasma proteins is unlikely to affect the connection of cabergoline with plasma proteins. It should be used with caution in conjunction with drugs that have a hypotensive effect.
In sealed manufacturer’s packaging, separately from food and feed, in a dry, dark place at a temperature of 5 ° C to 25 ° C. The medicinal product should be stored out of the reach of children and animals.
The shelf life of a medicinal product in a sealed package, subject to storage conditions, is 2 years from the date of manufacture. The shelf life after opening the bottle is 28 days.
Unit of issue of goods: bottle 15 ml